• Home
  • About
  • Employers by Category
    • Agriculture
    • Automation
    • Cancer Research
    • Cloud Software
    • Contract Research
    • Diagnostics
    • Drug Discovery
    • Genetic Testing
    • Genomics
    • Healthcare Services
    • Human Longevity
    • Medical Devices
    • Medical Imaging
    • Other
    • Pharmaceuticals
    • Research Institutes
    • Software Development
    • Synthetic Biology
  • Educational Programs
    • Undergraduate Computational Biology/Bioinformatics Programs
    • Undergraduate Biostatistics Programs
    • Summer Programs for Undergrads
    • Graduate Computational Biology/Bioinformatics Programs
    • Graduate Biostatistics Programs
  • Our Department
Main Menu
  • Home
  • About
  • Employers by Category
    • Agriculture
    • Automation
    • Cancer Research
    • Cloud Software
    • Contract Research
    • Diagnostics
    • Drug Discovery
    • Genetic Testing
    • Genomics
    • Healthcare Services
    • Human Longevity
    • Medical Devices
    • Medical Imaging
    • Other
    • Pharmaceuticals
    • Research Institutes
    • Software Development
    • Synthetic Biology
  • Educational Programs
    • Undergraduate Computational Biology/Bioinformatics Programs
    • Undergraduate Biostatistics Programs
    • Summer Programs for Undergrads
    • Graduate Computational Biology/Bioinformatics Programs
    • Graduate Biostatistics Programs
  • Our Department

Denali Therapeutics

151 Oyster Point Boulevard
South San Francisco, CA 94080
Drug Discovery
151 Oyster Point Boulevard
South San Francisco, CA 94080
www.denalitherapeutics.com

Description

Denali Therapeutics Inc. (‰Denali) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer‰’s disease, Parkinson‰’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).

Source: https://www.linkedin.com/company/denali-therapeutics/

Company Size: 51-200 employees

Connect

  • Twitter URL
  • LinkedIn URL

Contact Us

CMU Computational Biology Department
5000 Forbes Ave
Pittsburgh, PA 15213
(412) 268-4671
social@cbd.cmu.edu

Legal Info

Follow our Twitter list of companies!

My Tweets

Computational Biology Career Events

No upcoming events

Copyright © 2018 Carnegie Mellon University. All Rights Reserved

Login

Lost your password?